Buchanan RW, et al. “The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements,” Schizophrenia Bulletin (Jan. 2010): Vol. 36, No. 1, pp. 71–93. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19955390

Busch AB, et al. “Changes Over Time and Disparities in Schizophrenia Treatment Quality,” Medical Care (Feb. 2009): Vol. 47, No. 2, pp. 199–207. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19169121

Dixon LB, et al. “The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements,” Schizophrenia Bulletin (Jan. 2010): Vol. 36, No. 1, pp. 48–70. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19955389

Hogan M. “Updated Schizophrenia PORT Treatment Recommendations: A Commentary,” Schizophrenia Bulletin (Jan. 2010): Vol. 36, No. 1, pp. 104–06. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19892820

Hughes JR, et al. “Prevalence of Smoking Among Psychiatric Outpatients,” American Journal of Psychiatry (Aug. 1986): Vol. 143, No. 8, pp. 993–97. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3487983

Jones PB, et al. “Randomized Controlled Trial of the Effect on Quality of Life of Second- vs. First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1),” Archives of General Psychiatry (Oct. 2006): Vol. 63, No. 10, pp. 1079–87. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17015810

Kahn RS, et al. “Effectiveness of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: An Open Randomised Clinical Trial,” Lancet (March 29, 2008): Vol. 371, No. 9618, pp. 1085–97. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18374841

Kreyenbuhl J, et al. “The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009,” Schizophrenia Bulletin (Jan. 2010): Vol. 36, No. 1, pp. 94–103. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19955388

Lehman AF, et al. “Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition,” American Journal of Psychiatry (Feb. 2004): Vol. 161, No. 2, Suppl., pp. 1–56. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15000267

Lehman AF, et al. “The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003,” Schizophrenia Bulletin (Feb. 2004): Vol. 30, No. 2, pp. 193–217. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15279040

Lehman AF, et al. “Translating Research Into Practice: The Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations,” Schizophrenia Bulletin (Jan. 1998): Vol. 24, No. 1, pp. 1–10. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9502542

Lieberman JA, et al. “Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia,” New England Journal of Medicine (Sept. 22, 2005): Vol. 353, No. 12, pp. 1209–23. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16172203

Moore TA, et al. “The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia: 2006 Update,” Journal of Clinical Psychiatry (Nov. 2007): Vol. 68, No. 11, pp. 1751–62. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18052569

Schooler N, et al. “Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial,” American Journal of Psychiatry (May 2005): Vol. 162, No. 5, pp. 947–53. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15863797